古古斯特通过通过MAPK信号通路抑制糖解来抑制骨肉瘤的进展
Qijing Wang1, Xuhui Yuan2, Hongyan Li2
1Fujian Provincial Institute of Orthopedics, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China; Department of Orthopaedic, Affiliated Mindong of Fujian Medical University, Fuan, China.
概括
古古斯特 (GS) 通过通过MAPK途径抑制糖解来抑制骨髓瘤 (OS) 的进展. 这种植物性化合物显示出治疗OS的治疗潜力,OS是年轻人常见的骨癌.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 骨髓瘤 (OS) 是一种侵袭性骨癌,主要影响儿科和年轻成年人群.
- 化学抗药性往往限制了OS的治疗疗效.
- 古古尔斯特 (GS) 是一种植物固醇,具有抗瘤潜力,但其在OS中的作用尚不清楚.
研究的目的:
- 为了阐明GS在OS中的抗癌机制.
- 评估GS的治疗潜力,重点关注糖解和相关的信号通路.
主要方法:
- 在体外:细胞活力,殖民地形成,细胞亡,迁移试验,西部斑,RNA测序.
- 在体内:异种移植瘤模型来评估抗瘤疗效.
主要成果:
- GS减少了OS细胞的增殖,诱导了G2/M细胞周期的停止,并促进了细胞亡.
- GS抑制了OS细胞的迁移和入侵,影响了表皮-介质细胞过渡 (EMT) 蛋白.
- GS针对MAPK途径,损害糖解和改变细胞能量代谢.
- 在体内研究表明,GS减少了瘤生长,没有显著的全身毒性.
结论:
- 通过通过MAPK路径调节抑制糖解,GS有效地抑制OS进展.
- 作为治疗骨髓瘤治疗的治疗剂,GS显示出前途.
相关概念视频
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
TGF - β Signaling Pathway
7.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K
Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K


